Digital Contract

@csrf

Back

Survey Questionnaire Form

Professional

Doctor's details

@if (isset(session()->get('doctor')['vCentralCode']))

Doctor Name *

@else

Doctor Name *

@endif {{--

City *

--}} @if (isset(session()->get('doctor')['vCentralCode']))

Specialty *

@else

Specialty *

@endif

What is the most important expectation from medical communications when presenting drugs for pregnancy-related conditions? *

Delivering a balanced narrative that equally prioritizes therapeutic efficacy and maternal-fetal safety, guided by evidence-based recommendations and clinical context.

Ensuring precision in aligning content with approved product labeling, including gestational-specific dosing, route of administration, and relevant contraindications.

Strategically highlighting preferred therapeutic agents while minimizing comparative discussions that may create confusion or regulatory concerns.

Limiting discourse around known or potential adverse effects to maintain patient reassurance and prevent undue alarm, particularly during sensitive stages of pregnancy.

When introducing new contraceptive pills, what should be a priority? *

Clearly explaining the mechanism of action, typical and perfect-use effectiveness, and potential side effects in an easy-to-understand manner.

Addressing contraindications and precautions, particularly in women with comorbid conditions or on interacting medications.

Contextualizing the pill’s place in therapy relative to other available contraceptive options, including non-hormonal choices.

Highlighting real-world adherence challenges and counseling strategies to improve compliance.

Minimizing detailed clinical information to avoid overwhelming the audience.

All of the above

When discussing HRT for postmenopausal women, medical communication should: *

Provide long-term safety data

Avoid discussing risks like thromboembolism

Recommend usage without individual patient considerations

Prioritize marketing strategies over scientific facts

How should a conversation with a busy OBG clinician be initiated ? (Select all that apply) *

Greet professionally and briefly state the purpose

Start with unrelated small talk to build rapport

Insist on an extended meeting despite time constraints

Wait for an appropriate moment or request a suitable time, showing respect for patient priorities

When presenting a drug for PCOS management, what communication approach should be avoided? (Select all that apply) *

Providing an evidence-based, concise, and clinically relevant overview tailored to the physician’s specialty and patient base.

Presenting an overwhelming volume of technical data without context, making it difficult to extract actionable insights.

Using unsubstantiated or exaggerated claims that may compromise credibility and ethical standards.

Overemphasizing competitor shortcomings rather than focusing on the unique clinical value and patient fit of the therapy.

In the context of communicating OBG therapies such as hormone replacement or antenatal medications, which of the following is considered a good communication practice? (Select all that apply) *

Addressing clinical queries related to maternal health and treatment benefits

Using complex medical jargon that may reduce clarity

Keeping the discussion focused and clinically relevant

Using visual aids like charts or educational materials to support key messages

In the context of patient-centered communication regarding OBG therapies such as hormone replacement treatments or antenatal nutritional supplements which tone and delivery approach is most conducive to fostering informed decision-making, emotional reassurance, and sustained patient trust? *

Confident, clear, and respectful, encouraging open dialogue

Loud and dominant, emphasizing authority over interaction

Hesitant and unsure, potentially signaling uncertainty

Monotonous and disengaged, lacking emotional connection

What is the most appropriate way to handle a difficult question regarding side effects of an OBG-related therapy? *

Acknowledge the limitation and assure accurate follow-up information

Respond based on personal assumptions or opinions

Avoid the question to maintain the flow of discussion

Shift the conversation to an unrelated topic

What is considered an inappropriate non-verbal communication approach when meeting clinicians ? (Select all that apply) *

Maintaining eye contact, open posture, and showing attentiveness

Adopting a closed-off posture, such as crossing arms, combined with limited or avoided eye contact, potentially signaling disinterest or defensiveness

Frequently checking a mobile device during the discussion

Using exaggerated gestures that distract from the topic

How should a medical representative react if a clinician is uninterested or preoccupied *

Politely acknowledge the situation and offer to reschedule the discussion

Continue speaking in an attempt to regain attention

Leave abruptly without any closure

Speak louder and faster to force engagement

In which pregnancy-related conditions do you most commonly prescribe NMP (Natural Micronized Progesterone)? (Select all that apply) *

Recurrent pregnancy loss

Threatened abortion

Luteal phase defect

Prevention of Preterm Birth

Maintenance of pregnancy

What is the prevalence of patients requiring luteal phase support with progesterone in women seeking fertility in your clinical practice? *

0-10%

11-24%

25-49%

>50%

What is the prevalence of patients requiring intervention for prevention of preterm birth in your clinical practice? *

0-5%

6-10%

11-15%

>15%

For prevention of preterm birth, what is your preferred treatment of choice? *

Cervical cerclage

Cervical cerclage + Progesterone

Progesterone only

Any Other

Do you initiate progesterone therapy for prevention of preterm labour in high-risk pregnancies? If yes, please mention the details *

First trimester

Second trimester

Third trimester

Any Other

For how long do you prescribe vaginal progesterone women with a short cervix to prevent preterm birth? *

Until 20 weeks of gestation

Until 28 weeks of gestation

Until 34 to 36 weeks of gestation

Any Other

What is a key consideration when selecting the route of administration for progesterone therapy in OBG practice? *

Based on your observations of patient adherence, what is your preferred route of progesterone administration? *

How effectively does the medical representative inquire about your preferred natural micronized formulation and align the product discussion accordingly? *

Does the representative clearly explain the clinical value of progesterone therapy in women with recurrent pregnancy loss based on current evidence? *

When discussing cases of threatened miscarriage, does the representative appropriately address the clinical indicators for initiating progesterone therapy? *

Does the representative correctly identify and describe the ideal patient profiles who may benefit from progesterone prophylaxis for preterm birth? *

How confidently and accurately does the representative communicate the role of progesterone in managing short cervix during the second trimester to reduce the risk of preterm birth? *

How well does the representative convey the rationale for combining progesterone with estrogen in HRT for women with an intact uterus, especially in terms of preventing endometrial complications? *

Is the representative aware of and able to discuss key contraindications before initiating progesterone therapy? *

How effectively does the representative inform you about common side effects of progesterone therapy in gynecological and obstetric contexts?*